by Thomas Dworetzky
, Contributing Reporter | January 09, 2019
Clinical Laserthermia Systems (CLS) and Siemens Healthineers have inked a deal that will let Swedish-based CLS use Access-i software to connect its products with Healthineers' Magnetom MR scanners.
Access-i is fully compatible with the Healthineer's Magnetom portfolio and lets third parties integrate devices through interactive remote control and data access.
“The Access-i software and the agreement with Siemens Healthineers is yet another step toward CLS’s goal to build the next generation of integrated, workflow-optimized solutions for precision ablation,” said CLS chief commercial officer Dan Mogren in a company statement, adding that, “the realization of the agreement, which includes products and services supplied by Siemens Healthineers, will simplify and make a certain level of standardization of interfacing possible. The new product will enable CLS to offer a complete solution for therapeutically challenging soft tissue applications, including laser ablation of deep brain structures, and immune stimulating imILT treatment of cancer.”
CLS produces the TRANBERG Thermal Therapy System that provides minimally-invasive MR-guided focal laser ablation for tumors and soft tissue. It employs a non-cooled laser fiber technology able to optimize heat distribution – and needs no external cooling – cutting procedure times.
Now that the deal is signed, “CLS can start the work on interfacing the MR thermometry software, developed in collaboration with our partner Image Guided Therapy, to the world leading Magnetom Scanner portfolio of Siemens Healthineers,” added CLS CTO Stephan Dymling, calling the development project, which will employ Access-i to optimize real-time thermometry imaging during MR-guided laser ablation procedures, “exciting.”
In June, 2018, CLS inked a memorandum of understanding with Exact Imaging
aimed at optimizing high resolution micro-ultrasound guided focused laser ablation (FLA), with the intention of providing a solution for image-guided focal therapy to treat localized prostate cancer and benign prostatic hyperplasia (BPH).
"The intended collaboration will strengthen both companies' product offerings, expand the addressable market and further increase focus on sales,” Mogren said in a statement at the time, noting that, “ultrasound equipment is available today at almost all hospitals. However, we believe the 29 MHz ExactVu system, Exact Imaging's micro-ultrasound platform, dramatically increases the user's ability to see diseased tissue, to correctly place CLS instruments, and most importantly, to better monitor the FLA treatment itself. The intention is to offer the urologic market the safest, most complete and cost-effective solution for focal therapy of prostate cancer and BPH.”
Siemens made news in 2018 when when the industrial giant spun off its healthcare unit
, Healthineers, in an IPO on the Frankfurt stock exchange on March 15. The IPO was priced in the lower half of its 26-31 euro guidance range, and the sale of 150 million shares, or about 15 percent of Healthineers, raised 4.2 billion euros ($5.2 billion). It was Germany's second largest IPO in almost 20 years.
Siemens stated at the time that it planned to remain a majority shareholder for the long haul.
Calling the Healthineers “a truly global innovator with unique scale,” Bernd Montag, CEO of Siemens Healthineers, stressed at the time that given its positioning and global footprint, the organization will be “one of the main long-term beneficiaries of the significant structural growth inherent in our markets.”